Difficulty: Medium
Average Score: 94%
Practice
A pharmaceutical company is designing agents to treat the recurrent bronchospasm of bronchial asthma. Several agents that are antagonistic of bronchoconstriction are tested for efficacy in reducing the frequency and severity of acute asthmatic episodes. An inhaled drug reducing which of the following mediators is most likely to be effective in treating recurrent bronchial asthma?
Correct answer
C
Rationale
Th2 cytokines (C) reduction treats recurrent asthma . IL-4, IL-5, and IL-13 from TH2 cells drive late-phase inflammation, eosinophilia, and bronchospasm . Blocking them (e.g., anti-IL-13) cuts episodes (50% reduction). Th1 (A) aids granulomas. Amines (B) act early, not recurrently. Leukotrienes (D) enhance constriction but are secondary. C's role in chronicity unlike B's acute phase makes it key, per document.